Head-to-head clinical trials can be highly informative when choosing among multiple biologic options for the treatment of moderate to severe psoriasis. To date, only relatively short-term (varying from 12 weeks for most studies and up to 52 weeks in one study) head-to-head comparisons among different agents are available, and these studies do not always utilize uniform endpoints. Some studies use 75% improvement in Psoriasis Area and Severity Index (PASI 75), while others use 90% improvement in PASI (PASI 90) or even 100% improvement in PASI (PASI 100). In addition, the time of the endpoints varies from study to study. Nevertheless, these relatively short-term, head-to-head studies help determine comparative efficacy among the different agents. This table shows the results of the currently available head-to-head clinical trials of biologic agents for the treatment of patients with moderate to severe psoriasis.

<table>
<thead>
<tr>
<th>Greater Short-Term Efficacy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ustekinumab vs etanercept</td>
<td>Ustekinumab</td>
</tr>
<tr>
<td>Secukinumab vs etanercept</td>
<td>Secukinumab</td>
</tr>
<tr>
<td>Secukinumab vs ustekinumab</td>
<td>Secukinumab</td>
</tr>
<tr>
<td>Ixekizumab vs etanercept</td>
<td>Ixekizumab</td>
</tr>
<tr>
<td>Guselkumab vs adalimumab</td>
<td>Guselkumab</td>
</tr>
<tr>
<td>Brodalumab vs ustekinumab</td>
<td>Brodalumab</td>
</tr>
<tr>
<td>Ixekizumab vs ustekinumab</td>
<td>Ixekizumab</td>
</tr>
</tbody>
</table>

All doses used are FDA-approved doses. Etanercept dose is the high-dose 50 mg twice weekly.


